BOOM

Trending Searches

    SUPPORT
    BOOM

    Trending News

      • Fact Check 
        • Fast Check
        • Politics
        • Business
        • Entertainment
        • Social
        • Sports
        • World
      • Law
      • Explainers
      • News 
        • All News
      • Decode 
        • Impact
        • Scamcheck
        • Life
        • Voices
      • Media Buddhi 
        • Digital Buddhi
        • Senior Citizens
        • Videos
      • Web Stories
      • BOOM Research
      • BOOM Labs
      • Deepfake Tracker
      • Videos 
        • Facts Neeti
      • Home-icon
        Home
      • About Us-icon
        About Us
      • Authors-icon
        Authors
      • Team-icon
        Team
      • Careers-icon
        Careers
      • Internship-icon
        Internship
      • Contact Us-icon
        Contact Us
      • Methodology-icon
        Methodology
      • Correction Policy-icon
        Correction Policy
      • Non-Partnership Policy-icon
        Non-Partnership Policy
      • Cookie Policy-icon
        Cookie Policy
      • Grievance Redressal-icon
        Grievance Redressal
      • Republishing Guidelines-icon
        Republishing Guidelines
      • Fact Check-icon
        Fact Check
        Fast Check
        Politics
        Business
        Entertainment
        Social
        Sports
        World
      • Law-icon
        Law
      • Explainers-icon
        Explainers
      • News-icon
        News
        All News
      • Decode-icon
        Decode
        Impact
        Scamcheck
        Life
        Voices
      • Media Buddhi-icon
        Media Buddhi
        Digital Buddhi
        Senior Citizens
        Videos
      • Web Stories-icon
        Web Stories
      • BOOM Research-icon
        BOOM Research
      • BOOM Labs-icon
        BOOM Labs
      • Deepfake Tracker-icon
        Deepfake Tracker
      • Videos-icon
        Videos
        Facts Neeti
      Trending Tags
      TRENDING
      • #Operation Sindoor
      • #Pahalgam Terror Attack
      • #Narendra Modi
      • #Rahul Gandhi
      • #Waqf Amendment Bill
      • #Arvind Kejriwal
      • #Deepfake
      • #Artificial Intelligence
      • Home
      • Fact Check
      • Message Claiming Livfavir Is...
      Fact Check

      Message Claiming Livfavir Is Cheaper Than Glenmark's Fabiflu Is Misleading

      BOOM spoke to an executive of Livealth, manufacturer of Livfavir who said the company has withdrawn the drug.

      By - Shachi Sutaria |
      Published -  24 Jun 2020 6:12 PM IST
    • Boomlive
      Message Claiming Livfavir Is Cheaper Than Glenmarks Fabiflu Is Misleading

      A viral message claiming Livfavir a branded variant of the generic Favipiravir, manufactured by Livealth Biopharma is cheaper than Glenmark Pharmaceuticals' branded drug Fabiflu, is misleading.

      Favipiravir, a generic antiviral that is said to have worked against COVID-19 was launched by Glenmark Pharmaceuticals on June 20 under the brand name 'Fabiflu'. Fabiflu has been hotly debated on social media as the company published results but has not shared the data or methodology of the study.

      Also Read: Glenmark Launches FabiFlu For COVID-19 Treatment: All You Need To Know

      The viral message claims that while Fabiflu is priced at Rs. 103 per tablet; Livfavir is being sold at Rs.20 per tablet.

      BOOM reached out to Sanjay Patil, the director of Livealth Biopharma who clarified that the firm has withdrawn this product and are not planning to produce it in the future.

      "This is a fake message. It was a marketing error. We were supposed to write Rs.200 per tablet and had received permissions for the product. We, are however not planning to launch or sell this product now or in the future and have pulled out all the advertisements."

      The claim is viral across all social media platforms. The message also talks about Avigan. Avigan manufactured by Japanese firm Fujifilm Toyama Chemical, is a branded medicine of the same drug - Favipiravir. Japan has been using Avigan for treating influenza.


      *AN EYE OPENER*

      Fabiflu 200 mg. has been priced at Rs.103 per tablet by Glenmark. After my inquest, I found, already there exists a brand of Favipiravir in the Indian market with the brand name 'LIVFAVIR' marketed by a Mumbai based company Livealth Biopharma Private Limited --- pic.twitter.com/IcIRpsNeAz

      — 'Raja Raja' Unicuesrini1 (@universesrini) June 23, 2020

      The post is also viral on Facebook.

      Fact Check

      Livealth Biopharma took to Twitter as well as its Google updates to state that this message is fake.

      There is One Rumor circulating on Whatsapp linking our company Livealth Biopharma Pvt Ltd marketing product similar to "Favipiravir" of "Glenmark".
      We are not marketing any such product and have already withdrawn our product "Livfavir" which created this misunderstanding.

      — Livealth Biopharma Pvt Ltd (@livealth) June 24, 2020

      The drugmaker also emphasised that their turnovers were being exaggerated in the market. They revealed that their turnover is Rs. 10 crore and not Rs.120 crore as the message claims.The pharmaceutical has withdrawn all marketing material while stating that they will not be launching any such product in the market.

      BOOM also checked online pharmacies such as Indiamart, Medlife, Pharmeasy but did not find 'Livfavir' in any of their product listings.

      BOOM also could not find an any evidence supporting the other claim that Favipiravir/ Avigan is available for Rs 160 for 10 tablets in the country as claimed in the message. None of the online pharmacies listed Avigan in their products.

      Tags

      livealthfavipiravirfabifluglenmarkcovid-19livfavirCoronavirusCOVID-19FavipiravirLivealth Biopharma
      Read Full Article
      Claim :   Livfavir- favipiravir tablets are cheaper than Glenmark's fabiflu
      Claimed By :  Social media
      Fact Check :  Misleading
      Next Story
      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker. Please reload after ad blocker is disabled.
      X

      Subscribe to BOOM Newsletters

      👉 No spam, no paywall — but verified insights.

      Please enter a Email Address
      Subscribe for free!

      Stay Ahead of Misinformation!

      Please enter a Email Address
      Subscribe Now🛡️ 100% Privacy Protected | No Spam, Just Facts
      By subscribing, you agree with the Terms & conditions and Privacy Policy connected to the offer

      Thank you for subscribing!

      You’re now part of the BOOM community.

      Or, Subscribe to receive latest news via email
      Subscribed Successfully...
      Copy HTMLHTML is copied!
      There's no data to copy!